Fielder Capital Group LLC Buys New Stake in Danaher Co. (NYSE:DHR)

Fielder Capital Group LLC bought a new stake in Danaher Co. (NYSE:DHR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 878 shares of the conglomerate’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Everhart Financial Group Inc. purchased a new stake in shares of Danaher during the third quarter worth about $327,000. BluePath Capital Management LLC acquired a new position in Danaher during the 3rd quarter valued at approximately $44,000. Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Danaher by 25.0% in the third quarter. Pinnacle Wealth Management Advisory Group LLC now owns 2,117 shares of the conglomerate’s stock worth $525,000 after buying an additional 424 shares during the last quarter. Calamos Advisors LLC lifted its stake in shares of Danaher by 8.4% during the third quarter. Calamos Advisors LLC now owns 242,244 shares of the conglomerate’s stock worth $60,101,000 after buying an additional 18,776 shares during the period. Finally, First Merchants Corp increased its position in shares of Danaher by 7.8% in the 3rd quarter. First Merchants Corp now owns 38,679 shares of the conglomerate’s stock valued at $9,596,000 after acquiring an additional 2,807 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DHR shares. Royal Bank of Canada increased their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Raymond James raised their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. TD Cowen increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird boosted their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Bank of America increased their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $267.31.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,273 shares of company stock worth $26,813,819. Insiders own 10.90% of the company’s stock.

Danaher Price Performance

DHR traded down $0.98 during trading on Monday, hitting $247.40. The company’s stock had a trading volume of 1,593,955 shares, compared to its average volume of 2,755,556. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $183.25 billion, a price-to-earnings ratio of 41.93, a P/E/G ratio of 3.82 and a beta of 0.83. The business’s fifty day simple moving average is $248.40 and its 200 day simple moving average is $232.89. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.36 EPS. On average, equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.